# Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul

> **NCT00947362** · PHASE2,PHASE3 · COMPLETED · sponsor: **Waisenmedizin e. V. Promoting Access to Essential Medicine** · enrollment: 134 (actual)

## Conditions studied

- Wound Healing

## Interventions

- **OTHER:** Electro-thermo-coagulation
- **DRUG:** DAC N-055
- **DRUG:** saline

## Key facts

- **NCT ID:** NCT00947362
- **Lead sponsor:** Waisenmedizin e. V. Promoting Access to Essential Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-01
- **Primary completion:** 2007-12-15
- **Final completion:** 2007-12-15
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947362, "Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00947362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*